SCHEMBL56317

SCHEMBL56317

O=C(O)C(C(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.70
TDP1 Q9NUW8 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
LMNA P02545 5/20 0.59
CES2 O00748 2/20 0.59
CES1 P23141 2/20 0.59
CYP2D6 P10635 1/20 0.50
ALDH1A1 P00352 4/20 0.48
CYP3A4 P08684 2/20 0.48
MAPK1 P28482 2/20 0.48
MDM2 Q00987 1/20 0.45
DAO P14920 1/20 0.44
TSHR P16473 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 2/20 0.43
PTGS1 P23219 2/20 0.43
PTGS2 P35354 2/20 0.43
CXCR1 P25024 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1667152 0.91 TDP1 (0.67) SRCTDP1L3MBTL1LMNACES2
SCHEMBL29586362 0.88 TDP1 (0.64) SRCTDP1L3MBTL1LMNACES2
SCHEMBL28025801 0.88 TDP1 (0.64) SRCTDP1L3MBTL1LMNACES2
SCHEMBL2122042 0.86 SRC (0.57) SRCTDP1L3MBTL1LMNACES2
SCHEMBL9356311 0.86 SRC (0.52) SRCTDP1L3MBTL1LMNACES2
SCHEMBL8990032 0.84 TDP1 (0.59) SRCTDP1L3MBTL1LMNACES2
SCHEMBL148725 0.83 SRC (1.00) SRCTDP1L3MBTL1LMNACES2
SCHEMBL70165 0.83 SRC (1.00) SRCTDP1L3MBTL1LMNACES2
SCHEMBL23457197 0.83 TDP1 (0.57) SRCTDP1L3MBTL1LMNACES2
SCHEMBL600680 0.83 TDP1 (0.57) SRCTDP1L3MBTL1LMNACES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105339445-B Industrial deinking of ink compositions 西康制造有限公司 2019-07-05 CN claimed
CN-105339445-A Industrial deinking of ink compositions XEIKON IP BV 2016-02-17 CN claimed
EP-0326915-B1 A LOCALLY ADMINISTRABLE THERAPEUTIC COMPOSITION FOR INFLAMMATORY DISEASE Senju Pharmaceutical Co., Ltd. (JP) 1992-09-02 EP claimed
US-4910225-A Benzoylphenylacetic acid SENJU PHARMACEUTICAL CO., LTD. (JP) 1990-03-20 US claimed
EP-0326915-A1 A locally administrable therapeutic composition for inflammatory disease Senju Pharmaceutical Co., Ltd. (JP) 1989-08-09 EP claimed
US-3962303-A Novel benzoylphenylacetic acid derivatives ROUSSEL-UCLAF (FR) 1976-06-08 US claimed
US-3931286-A Novel benzoylphenylacetic acid derivatives ROUSSEL-UCLAF (FR) 1976-01-06 US claimed
JP-2124817-A None JP disclosed
CN-115279206-A Flavor composition 弗门尼舍有限公司 2022-11-01 CN disclosed
WO-2020231796-A1 FLEXIBLE SUBSTRATE, METHOD FOR THE MANUFACTURE THEREOF, AND FLEXIBLE ELECTRONIC ASSEMBLIES COMPRISING THE FLEXIBLE SUSBTRATE SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2020-11-19 WO disclosed
US-20200360326-A1 Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid BAUSCH & LOMB INCORPORATED 2020-11-19 US disclosed
EP-3738994-A1 FLEXIBLE SUBSTRATE, METHOD FOR THE MANUFACTURE THEREOF, AND FLEXIBLE ELECTRONIC ASSEMBLIES COMPRISING THE FLEXIBLE SUSBTRATE SABIC Global Technologies B.V. (NL) 2020-11-18 EP disclosed
US-10646435-B2 Pasty bio-adhesive sustained release compositions CARE & PHARMA PERSPECTIVES SA (CH) 2020-05-12 US disclosed
US-3975531-A ANTIINFLAMMATORY A. H. ROBINS COMPANY, INCORPORATED (US) 1976-08-17 US disclosed
US-3962303-A Novel benzoylphenylacetic acid derivatives ROUSSEL-UCLAF (FR) 1976-06-08 US disclosed
US-3962303-A Novel benzoylphenylacetic acid derivatives ROUSSEL-UCLAF (FR) 1976-06-08 US disclosed
US-3962303-A Novel benzoylphenylacetic acid derivatives ROUSSEL-UCLAF (FR) 1976-06-08 US disclosed
US-3931286-A Novel benzoylphenylacetic acid derivatives ROUSSEL-UCLAF (FR) 1976-01-06 US disclosed
US-3931286-A Novel benzoylphenylacetic acid derivatives ROUSSEL-UCLAF (FR) 1976-01-06 US disclosed
US-3931286-A Novel benzoylphenylacetic acid derivatives ROUSSEL-UCLAF (FR) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200360326-A1 Aqueous Liquid Composition Containing 2-Amino-3-(4-Bromobenzoyl)Phenylacetic Acid AADAT, UACA, IL4 SRC 3535/4885TDP1 3215/4885L3MBTL1 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.